Orphanet: ENDEAVOR: A Randomized, Open label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma UK
x

Search for a clinical trial

* (*) mandatory field

ENDEAVOR: A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma - UK

  • Type of clinical trial : Drug clinical trial
  • Recruiting project : Yes
  • Status : Ongoing trial
  • Funding body(ies) :
  • Geographic coverage : Global
  • Sponsor : Onyx pharmaceuticals inc.
  • Website
    • Phase : III
  • Principal investigator of clinical trial

  • Dr Faith DAVIES
  • National Cancer Research Institute (NCRI)
  • P O Box 123, Lincoln's Inn Fields
  • LONDON WC2A 3PX
  • UNITED KINGDOM
  • More information
  • Phone  : 44 (0)203 469 8460
  • Fax  : -
  • Website
  • Contact secretary  :
Last update: May 2017

Additional information

The documents contained in this web site are presented for information purposes only. The material is in no way intended to replace professional medical care by a qualified specialist and should not be used as a basis for diagnosis or treatment.